companies / anagramtx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-14 json
| total_raised | 285,000,000285.0M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Natick, MA | |
| industry | unknown | |
| stage | series-b+ |
Anagram Therapeutics develops oral enzyme replacement therapies for rare malabsorption and nutrient metabolism disorders. Its lead candidate ANG003 is in Phase 2 trials for cystic fibrosis and exocrine pancreatic insufficiency in infants, children, and adults. Proprietary enzyme stabilization technology extends activity through the GI tract where competitors degrade.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-05-08 | series-c | 250,000,000250.0M | null | ○ |
Nginx, Bootstrap 5.3.2, Google Analytics, Google Tag Manager, jQuery CDN, jsDelivr, ExpressionEngine, DoubleClick Floodlight, CodeIgniter, WordPress, PHP, MySQL
| fact | status | src |
|---|---|---|
| Series C, $250.0M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes